Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Net sales for the quarter were $1.1 million reflecting 63 percent growth from the previous quarter.
- Net sales for the quarter were $1.1 million reflecting 63 percent growth from the previous quarter.
- Lexicon is initiating a Phase 3 study of sotagliflozin in HCM, with an expected study start mid-year 2024.
- Results from Two Large US Integrated Health System
Revenues: Revenues for the first quarter of 2024 were $1.1 million, primarily from the commercialization of INPEFA. - Lexicon management will hold a live conference call and webcast today at 5:00 pm ET / 4:00 pm CT to review its financial and operating results and to provide a general business update.